

2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Anne R. Bass,¹  Eliza Chakravarty,² Elie A. Akl,³ Clifton O. Bingham,⁴  Leonard Calabrese,⁵ 
Laura C. Cappelli,⁴  Sindhu R. Johnson,⁶  Lisa F. Imundo,⁷ Kevin L. Winthrop,⁸  Reuben J. Arasaratnam,⁹
Lindsey R. Baden,¹⁰ Roberta Berard,¹¹  S. Louis Bridges Jr.,¹  Jonathan T. L. Cheah,¹² Jeffrey R. Curtis,¹³ 
Polly J. Ferguson,¹⁴ Ida Hakkarinen,¹⁵ Karen B. Onel,¹ Grayson Schultz,¹⁶ Vidya Sivaraman,¹⁷
Benjamin J. Smith,¹⁸  Jeffrey A. Sparks,¹⁰  Tiphane P. Vogel,¹⁹  Eleanor Anderson Williams,²⁰
Cassandra Calabrese,⁵ Joanne S. Cunha,²¹ Joann Fontanarosa,²² Miriah C. Gillispie-Taylor,¹⁹
Elena Gkrouzman,¹²  Priyanka Iyer,²³ Kimberly S. Lakin,¹  Alexandra Legge,²⁴ Mindy S. Lo,²⁵ 
Megan M. Lockwood,²⁶  Rebecca E. Sadun,²⁷  Namrata Singh,²⁸ Nancy Sullivan,²² Herman Tam,²⁹ 
Marat Turgunbaev,³⁰ Amy S. Turner,³⁰  and James Reston²²

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the clinician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions, and drug formularies or other third-party analyses that cite ACR guidelines should state this. These recommendations cannot adequately convey all uncertainties and nuances of patient care.

The ACR is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service.

Objective. To provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).

Methods. This guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. It also adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists and a guideline methodologist drafted clinical population, intervention, comparator, outcomes (PICO) questions. A review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced an evidence report. An expert Voting Panel reviewed the evidence and formulated recommendations. The panel

This article is published simultaneously in *Arthritis & Rheumatology*.
Supported by the American College of Rheumatology.

¹Anne R. Bass, MD, S. Louis Bridges Jr., MD, PhD, Karen B. Onel, MD, Kimberly S. Lakin, MD, MS: Hospital for Special Surgery and Weill Cornell Medicine, New York, New York; ²Eliza Chakravarty, MD: Oklahoma Medical Research Foundation, Oklahoma City; ³Elie A. Akl, MD, MPH, PhD: American

University of Beirut, Beirut, Lebanon; ⁴Clifton O. Bingham, MD, Laura C. Cappelli, MD, MHS, MS: Johns Hopkins Medicine, Baltimore, Maryland; ⁵Leonard Calabrese, DO, Cassandra Calabrese, DO: Cleveland Clinic Foundation, Cleveland, Ohio; ⁶Sindhu R. Johnson, MD, PhD: Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada; ⁷Lisa F. Imundo, MD: Columbia University Irving Medical Center,

included adult and pediatric rheumatology providers, infectious diseases specialists, and patient representatives. Consensus required $\geq 70\%$ agreement on both the direction and strength of each recommendation.

Results. This guideline includes expanded indications for some vaccines in patients with RMDs, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy. Safe approaches to the use of live attenuated vaccines in patients taking immunosuppressive medications are also addressed. Most recommendations are conditional and had low quality of supporting evidence.

Conclusion. Application of these recommendations should consider patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.

INTRODUCTION

Rheumatic and musculoskeletal diseases (RMDs) (1,2) and immunosuppressive medications used to treat them place patients at higher risk of vaccine-preventable infections and of more serious complications of infection. Vaccines have long been used to reduce illness from common viral and bacterial pathogens, and standardized vaccine schedules for children and adults have been widely adopted for use in both healthy people and those with chronic medical conditions (3,4). However, the immunogenicity and safety of vaccines may differ in patients with RMDs compared to the general population, and patients with RMDs may benefit from modified vaccine indications and/or adjustments to vaccination or medication schedules. Issues related to vaccination and medication management at the time of vaccination apply across diseases, and thus, this guideline is meant to help in the management of vaccines for all children and adults with RMDs in the US. The target audience is limited to rheumatology providers in the US because the epidemiology of vaccine-preventable infections and the availability of specific vaccines vary across the globe. However, providers in other countries may also find the guideline useful. A list of specific medications, vaccinations, and RMDs addressed in this guideline is found in Table 1, and a glossary of terms commonly used in this guideline can be found in Table 2.

Avacopan and bimekizumab, the pneumococcal vaccines PCV15 and PCV20, and the smallpox/monkeypox vaccine were not included in the formal evidence review because they were not approved at the time of the project plan. Antipyretic medications

such as nonsteroidal antiinflammatory drugs and acetaminophen were also not included. Although a few randomized controlled trials (RCTs) have demonstrated blunted antibody responses with antipyretics, this was seen after primary vaccination only, and not after booster (5) or influenza vaccination (6). Observational studies also suggest that they have minimal-to-no impact on antibody responses to vaccination (5,7). Vaccinations against COVID-19 are not included in this guideline because, given the fast-changing nature of the pandemic and the COVID-19-related literature, there was concern that recommendations would be obsolete well before guideline publication. COVID-19 vaccinations will be incorporated into a future guideline update once the pertinent literature has stabilized. We refer readers to the American College of Rheumatology (ACR) COVID-19 vaccine guidance (8) and to the Centers for Disease Control and Prevention (CDC) website (9) for information on COVID-19 vaccines for patients with compromised immunity. Finally, we refer readers to the Advisory Committee on Immunization Practices (ACIP) (10) and the American Academy of Pediatrics (AAP) (11) vaccination guidelines for any other topics not addressed herein. This study did not involve human subjects, and therefore, approval from Human Studies Committees was not required.

The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination should be administered to all RMD patients taking immunosuppressive medication; 2) recombinant zoster vaccination is recommended for RMD patients >18 years of age taking immunosuppressive medication; 3) methotrexate should be held

New York, New York; ⁸Kevin L. Winthrop, MD, MPH: Oregon Health & Science University, Portland; ⁹Reuben J. Arasaratnam, MD: VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas; ¹⁰Lindsey R. Baden, MD, MSc, Jeffrey A. Sparks, MD, MMSc: Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; ¹¹Roberta Berard, MD: Children's Hospital, London Health Sciences Centre, London, Ontario, Canada; ¹²Jonathan T. L. Cheah, MBBS, Elena Gkrouzman, MD: University of Massachusetts Chan Medical School, Worcester; ¹³Jeffrey R. Curtis, MD, MS, MPH: University of Alabama at Birmingham; ¹⁴Polly J. Ferguson, MD: University of Iowa Carver College of Medicine, Iowa City; ¹⁵Ida Hakkarinen, MS: Greenbelt, Maryland; ¹⁶Grayson Schultz, MS: Athens, Ohio; ¹⁷Vidya Sivaraman, MD: The Ohio State University and Nationwide Children's Hospital, Columbus; ¹⁸Benjamin J. Smith, DMSc, PA-C, DFAAPA: Florida State University College of Medicine, Tallahassee; ¹⁹Tiphany P. Vogel, MD, PhD, Miriah C. Gillispie-Taylor, MD: Baylor College of Medicine, Houston, Texas; ²⁰Eleanor Anderson Williams, MD: The Permanente Medical Group, Union City, California; ²¹Joanne S. Cunha, MD: Brown University, Brown Physicians Inc., and Providence Veterans Affairs Medical Center, East Providence, Rhode Island;

²²Joann Fontanarosa, PhD, Nancy Sullivan, BA, James Reston, PhD, MPH: ECRI Institute, Plymouth Meeting, Pennsylvania; ²³Priyanka Iyer, MD: University of California Irvine Medical Center, Orange; ²⁴Alexandra Legge, MD, MSc: Dalhousie University and QEII Health Sciences Centre, Halifax, Nova Scotia, Canada; ²⁵Mindy S. Lo, MD, PhD: Boston Children's Hospital, Boston, Massachusetts; ²⁶Megan M. Lockwood, MD: Georgetown University Hospital, Washington, DC; ²⁷Rebecca E. Sadun, MD, PhD: Duke University, Durham, North Carolina; ²⁸Namrata Singh, MD: University of Washington, Seattle; ²⁹Herman Tam, MBBS, MSc: British Columbia Children's Hospital, Vancouver, British Columbia, Canada; ³⁰Marat Turgunbaev, MD, MPH, Amy S. Turner: American College of Rheumatology, Atlanta, Georgia.

Author disclosures are available at <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Facr.25045&file=acr25045-sup-0001-Disclosureform.pdf>.

Address correspondence via email to Anne R. Bass, MD, at bassa@hss.edu.

Submitted for publication August 8, 2022; accepted in revised form October 13, 2022.

Table 1. Guideline scope*

Medications		Vaccines†		Rheumatic and musculoskeletal disorders
Immunosuppressive	Nonimmunosuppressive	Non-live attenuated	Live attenuated	
Glucocorticoids	Hydroxychloroquine	Seasonal influenza	Influenza (intranasal)	Inflammatory arthropathies
Prednisone	Sulfasalazine	Standard dose, high	MMR	Rheumatoid arthritis
Methylprednisolone	Colchicine	dose, adjuvanted	Rotavirus	Psoriatic arthritis
Dexamethasone	Apremilast	Pneumococcal	Typhoid (oral)	Ankylosing spondylitis
Hydrocortisone	Denosumab	PPSV23, PCV13‡	Varicella	Spondyloarthritis
csDMARDs	IVIG	Other	Yellow fever	Enthesitis-related arthritis
Methotrexate		Hemophilus influenza b	Zoster	IBD-associated arthritis
Leflunomide		Hepatitis A		Juvenile idiopathic arthritis
Azathioprine		Hepatitis B		Connective tissue diseases
Mycophenolate mofetil/ mycophenolic acid		Human papillomavirus		Systemic lupus erythematosus
Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin)		Inactivated polio		Sjögren's syndrome
Cyclophosphamide		Meningococcus B		Systemic sclerosis
bDMARDs		Meningococcus ACWY		Idiopathic inflammatory myopathies
TNF inhibitors (etanercept, adalimumab, certolizumab, golimumab, infliximab)		Tetanus toxoid/Td/Tdap		Mixed connective tissue disease
IL-6R inhibitors (tocilizumab, sarilumab)		Typhoid (injectable)		Undifferentiated connective tissue disease
IL-17 inhibitors (secukinumab, ixekizumab)		Zoster subunit		Antiphospholipid antibody syndrome
IL-12/23 inhibitors (ustekinumab)				Vasculitides
IL-23 inhibitors (guselkumab, tildrakizumab, risankizumab)				Granulomatosis with polyangiitis
IL-1 inhibitors (anakinra, canakinumab, rilonacept)				Microscopic polyangiitis
T cell costimulation inhibitor (CTLA4-Ig/ abatacept)				Eosinophilic granulomatosis with polyangiitis
B cell-depleting agents (rituximab, ocrelizumab, obinituzumab)				Giant cell arteritis
BLyS/BAFF inhibitors (belimumab, tabalumab)				Polyarteritis nodosa
Interferon-α receptor inhibitor (anifrolumab)				Takayasu arteritis
tsDMARDs				Cryoglobulinemic vasculitis
JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, ruxolitinib)				Relapsing polychondritis
				Behçet's disease
				Kawasaki disease
				IgA vasculitis (Henoch-Schönlein)
				Primary CNS vasculitis
				Goodpasture's syndrome (anti-GBM)
				Cogan's syndrome
				Cutaneous small vessel vasculitis
				Rheumatoid vasculitis
				Urticarial vasculitis
				Other inflammatory disorders
				Sarcoidosis
				Adult-onset Still's disease
				Polymyalgia rheumatica
				Gout
				Pseudogout
				IgG4-related disease
				Autoinflammatory disorders

* MMR = measles, mumps, and rubella (vaccine); PPSV23 = pneumococcal polysaccharide vaccine; PCV13 = pneumococcal conjugate vaccine; csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; IVIG = intravenous immunoglobulin; IBD = inflammatory bowel disease; bDMARDs = biologic DMARDs; TNF = tumor necrosis factor; IL-6R = interleukin-6 receptor; BLyS = B lymphocyte stimulator; tsDMARDs = targeted synthetic DMARDs; CNS = central nervous system; anti-GBM = anti-glomerular basement membrane (disease).

† COVID-19 vaccines were not included in this guideline because of the fast-changing face of the pandemic and related literature.

‡ The recently approved pneumococcal vaccines, PCV15 and PCV20, were not included in the evidence review but are discussed in the text with reference to current Centers for Disease Control and Prevention guidelines.

for 2 weeks after influenza vaccination if disease activity allows;
4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking

high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab

Table 2. Glossary of terms

Term	Definition
Adjuvant	An ingredient used in some vaccines that helps create a stronger immune response in patients receiving the vaccine
Immunogenicity	The ability of a vaccine to elicit an immune response
Reactogenicity	Typical symptoms (e.g., fever, sore arm, muscle aches) that occur shortly (days) after vaccine administration either at the site of vaccination or systemically
Seroconversion	Development of antibodies to a pathogen, elicited by a vaccine (or infection), in the blood of an individual who previously did not have detectable antibodies
Seroprotection	An antibody level capable of protecting against infection or disease
Titer	Numerical value indicating the level of antibody against a particular pathogen

dose; and 6) infants exposed to tumor necrosis factor inhibitors (TNFi) in utero should receive rotavirus vaccination in the first 6 months of life.

METHODS

This guideline follows ACR policy guiding management of conflicts of interest and disclosures (<https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines>) and the ACR guideline development process, which includes Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (12,13), and adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria (14). Supplementary Appendix 1, available on the *Arthritis Care & Research* website at <http://onlinelibrary.wiley.com/doi/10.1002/acr.25045>, includes a detailed description of the methods. Briefly, the guideline team drafted clinical population, intervention, comparator, outcomes (PICO) questions (see Supplementary Appendix 2, available on the *Arthritis Care & Research* website at <http://onlinelibrary.wiley.com/doi/10.1002/acr.25045>). The literature review team performed a systematic literature review for the PICO questions, graded the quality of evidence (high, moderate, low, very low), and produced the evidence report (see Supplementary Appendix 3, available on the *Arthritis Care & Research* website at <http://onlinelibrary.wiley.com/doi/10.1002/acr.25045>). An expert Voting Panel reviewed the evidence report and then formulated and voted on recommendations. Additionally, a virtual Patient Panel reviewed the evidence and provided patient perspectives and preferences for consideration by the Voting Panel. The Patient Panel consisted of 9 patients with a variety of adult and pediatric RMDs and was moderated by a member of the core team (EC).

Voting Panel consensus required $\geq 70\%$ agreement on both the direction (for or against) and strength (strong or conditional) of each recommendation, as per ACR practice. According to

GRADE, a recommendation is categorized as strong if the panel is very confident that the benefits of an intervention clearly outweigh the harms (or vice versa); a conditional recommendation denotes uncertainty regarding the balance of benefits and harms, such as when the evidence quality is low or very low, or when costs are expected to impact the decision. Thus, for conditional recommendations, incorporation of patient preferences is particularly essential, acknowledging that patient preferences are an important part of all clinical decision-making. Rosters of the Core Leadership Team, Literature Review Team, Voting Panel, and Patient Panel are included in Supplementary Appendix 4, available on the *Arthritis Care & Research* website at <http://onlinelibrary.wiley.com/doi/10.1002/acr.25045>.

The following guiding principles were used in this guideline: 1) indicated vaccinations should be given to patients whenever possible; 2) this guideline is complementary to recommendations from the ACIP (10) and the AAP (15); 3) the decision to hold a medication before or after vaccination should consider the patient's disease, disease activity, and risk for vaccine-preventable infection; and 4) shared decision-making with patients is a key component of any vaccination strategy.

RESULTS/RECOMMENDATIONS

Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression

Influenza vaccination

For patients with RMD age ≥ 65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination.

Any influenza vaccine is preferred over no influenza vaccine, and vaccination "today" is preferred over delay. Therefore, if high-dose or adjuvanted influenza vaccine is not available in the clinic during a patient visit when influenza vaccination is indicated, then standard-dose influenza vaccine should be administered. This caveat also applies in instances when insurance restrictions may preclude administration of high-dose or adjuvanted influenza vaccination to patients <65 years of age.

High-dose influenza vaccine is a quadrivalent vaccine containing 4 times the antigen as the standard-dose vaccine. Two RCTs in rheumatoid arthritis (RA) patients showed higher seroconversion rates in younger patients receiving high-dose vaccination compared to standard-dose vaccination with no safety signal (16,17). The adjuvanted influenza vaccine is a standard-dose quadrivalent vaccine containing the MF59 adjuvant, which elicits a strong antigenic response without the need for a higher antigen dose. No studies of the adjuvanted influenza vaccination in RMD patients age <65 years were identified in the literature search, but there

have been no safety issues seen with adjuvants in general, although they may be associated with greater reactogenicity (18).

Pneumococcal vaccination

For patients with RMD age <65 years who are taking immunosuppressive medication, pneumococcal vaccination is strongly recommended.

Patients with RMDs taking immunosuppressive medication may be at increased risk of pneumococcal infection (19,20). Multiple observational studies have evaluated the prime boost method of pneumococcal vaccination, with a pneumococcal conjugate vaccine (PCV13 or PCV15), followed 2 months later by a dose of the pneumococcal polysaccharide vaccine (PPSV23). A single-dose PCV20 vaccine is now approved in the US (21) and is likely to supplant this 2-dose strategy in the not-too-distant future, at least in adults. PCV15 and PCV20 polysaccharide conjugates are not currently approved for use in children in the US; but this too may soon change. The CDC currently recommends PCV15 followed by PPSV23 one year later, or PCV20, for adults <65 years taking immunosuppressive medications who were not previously vaccinated against pneumococcus, however, we recommend reference to CDC guidelines when choosing a specific pneumococcal vaccination strategy because this area is rapidly changing (21).

There are few studies evaluating the impact of disease-modifying antirheumatic drugs (DMARDs) on conjugate pneumococcal vaccines. The ACIP recommends administering pneumococcal vaccination to individuals age >18 years with certain chronic medical conditions and those taking immunosuppressive medication (10,22). The CDC and AAP recommend the primary PCV13 series to all children <2 years of age and PPSV23 vaccination to children age ≥2 years with underlying medical conditions (15).

Recombinant varicella-zoster virus (VZV) vaccination

For patients with RMD age >18 years who are taking immunosuppressive medication, administering the recombinant VZV vaccine is strongly recommended.

Patients with RMDs such as systemic lupus erythematosus (SLE) and RA are at higher risk of herpes zoster than older adults recommended for vaccination (23). Although the literature search identified no publications that specifically addressed recombinant VZV vaccination in patients with RMDs who are <50 years of age, this vaccine has been shown to be safe and effective in immunosuppressed patients undergoing renal transplantation (24) and autologous stem cell transplantation (25) and in patients with hematologic malignancies, many of whom are <50 years of age (26,27). The ACIP recommends recombinant VZV vaccination for individuals >18 years and <50 years of age who are immunocompromised and for the general public age ≥50 years (10). One retrospective study

demonstrated mild disease flares in some patients around the time of vaccination (28), and reactogenicity is common with this vaccine (26).

Human papillomavirus (HPV) vaccination

For patients with RMD age >26 years and <45 years who are taking immunosuppressive medication and not previously vaccinated, vaccination against HPV is conditionally recommended.

Patients taking immunosuppressive medication may be at increased risk of cervical dysplasia and cervical cancer (29–33). Two studies of young patients with SLE (mean age 38 years and 26 years in the 2 studies, respectively) demonstrated that vaccination against HPV was immunogenic and well tolerated (34,35). The ACIP recommends HPV vaccination for individuals ages 11–26 years. For those ages 26–45 years who have not been previously vaccinated, ACIP recommends HPV vaccination based on shared decision-making (10). The benefits of vaccination after age 45 years diminish due to the greater likelihood of previous exposure to HPV.

Whether to hold immunosuppressive medication at the time of non-live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare (Table 3).

Methotrexate

For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows.

For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended.

For patients with RMD, continuing immunosuppressive medications around the time of other (non-influenza) non-live attenuated vaccinations is conditionally recommended.

Many observational studies (36,37) suggest that methotrexate significantly blunts but does not completely abrogate the immunogenicity of influenza vaccination. Two RCTs demonstrated a beneficial impact of holding methotrexate around the time of influenza vaccination on vaccine immunogenicity (38,39). Assessment of flare risk and shared decision-making with the patient is recommended when deciding whether methotrexate should be held. Non-rheumatology providers (e.g., general pediatricians and internists) are encouraged to give influenza vaccination even if they are unsure as to whether to hold methotrexate, and then to consult with the patient's rheumatologist, rather than miss a vaccination opportunity. The literature review did not identify any studies that addressed holding medications in the context of vaccines other than for influenza. However, 2 studies published after completion of the literature review suggested that

Table 3. Medication management at the time of non-live attenuated vaccine administration

	Influenza vaccination	Other non-live attenuated vaccinations
Methotrexate	Hold methotrexate for 2 weeks <i>after vaccination</i> *	Continue methotrexate
Rituximab	Continue rituximab†	Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination
Immunosuppressive medications other than methotrexate and rituximab	Continue immunosuppressive medication	Continue immunosuppressive medication

□ = Conditional recommendation.

* Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient's rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.

† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.

holding methotrexate at the time of COVID-19 vaccination is associated with greater vaccine immunogenicity (40,41).

The literature review identified no studies that directly addressed the impact of holding medications other than methotrexate at the time of influenza vaccination. Two RCTs performed in patients initiating TNFi versus placebo demonstrated similar responses to influenza vaccination in the 2 arms (42,43). Data on other biologic DMARDs and their relationship to influenza vaccine responses are much more limited (44–47).

Rituximab

For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due.

For patients with RMD receiving rituximab, *deferring* non-live attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and *delaying* rituximab for 2 weeks after vaccination, is conditionally recommended.

Influenza vaccine responses are greater when the vaccine is administered later rather than earlier after rituximab (48–50). Rituximab has also been shown to blunt responses to pneumococcal polysaccharide PPSV23 vaccination (51,52). Because of the seasonal nature of influenza, influenza vaccination is conditionally recommended to be given on schedule to patients receiving rituximab. For other non-live attenuated vaccinations, deferring vaccination until the next rituximab dose will improve vaccine immunogenicity. However, patients could also be vaccinated in the interest of acquiring some immunity and then revaccinated later (influenza vaccination could also be repeated using this same rationale). Whenever possible, vaccinations should be administered prior to rituximab initiation. Rituximab should be delayed for at least 2 weeks after any vaccination to allow time for the patient to develop an immune response, assuming that disease activity allows.

Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or with active disease (Table 4).

Glucocorticoids

Whether to administer non-live attenuated vaccinations to patients taking glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity.

For patients with RMD who are taking the equivalent of prednisone ≤ 10 mg daily, administering any non-live vaccinations is strongly recommended.

For patients with RMD who are taking the equivalent of prednisone > 10 mg daily but < 20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended.

For patients with RMD taking the equivalent of prednisone ≥ 20 mg daily, administering influenza vaccination is conditionally recommended.

For patients with RMD who are taking the equivalent of prednisone ≥ 20 mg daily, *deferring* non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone < 20 mg daily is conditionally recommended.

Most studies that have compared prednisone < 10 mg daily to prednisone ≥ 10 mg daily found that the higher dosages did reduce influenza vaccine immunogenicity (53–55). Several studies that defined high-dose glucocorticoids as prednisone ≥ 20 mg daily observed that they blunted patients' vaccine response (56–58). Two studies that examined glucocorticoid dosage as a continuous variable identified a dose-response relationship while suggesting against a specific dose threshold (57,58). Evidence for the impact of glucocorticoids on responses to other vaccines is less consistent (59–61). For some vaccines, humoral responses can be measured and revaccination considered in those with an inadequate response.

Given the importance of timely influenza vaccination, a conditional recommendation was made to administer influenza vaccination to patients receiving the equivalent of prednisone ≥ 20 mg daily. For vaccines other than for influenza, a conditional

Table 4. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids regardless of disease activity

	Influenza vaccination	Other non-live attenuated vaccinations
Prednisone ≤ 10 mg daily*	Give	Give
Prednisone > 10 mg and < 20 mg*	Give	Give
Prednisone ≥ 20 mg daily*	Give	Defer†

■ = Strong recommendation.

□ = Conditional recommendation.

* Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.

† Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone < 20 mg daily.

recommendation was made to delay vaccination until the dose is lower to maximize vaccine efficacy. It is understood, however, that some patients may not be able to delay, e.g., children who require vaccination for school entry.

Disease activity

Whether to defer vaccination in patients with high disease activity to maximize vaccine immunogenicity and/or avoid worsening disease activity.

For patients with RMD, giving non-live attenuated vaccinations is conditionally recommended regardless of patients' disease activity.

Patients with RMD often express concern about whether vaccination can induce a disease flare, but the vast majority of studies failed to show any increased rate of flare after influenza vaccination. The results were similar for other vaccinations, although the quality of the evidence was low. Strong concerns, however, were expressed among the Patient Panel about the potential for vaccines to cause a disease flare, and shared decision-making is particularly important in this setting. Most studies suggest that increased disease activity does not impact vaccine immunogenicity (53,62), although one study did show lower seroconversion rates in pediatric lupus patients with a Systemic Lupus Erythematosus Disease Activity Index score of > 8 who were vaccinated against influenza (57).

Managing immunosuppressive therapy at the time of live attenuated vaccination to avoid vaccine-associated illness (Table 5).

For patients with RMD who are taking immunosuppressive medication, deferring live attenuated vaccines is conditionally recommended.

For patients with RMD, holding immunosuppressive medication for an appropriate period before and 4 weeks after live attenuated virus vaccination is conditionally recommended.

For some live attenuated virus vaccines, such as for oral polio, oral typhoid, and influenza, there are inactivated alternatives

that can be safely given to RMD patients taking immunosuppressive medication.

Conventional DMARDs. Two observational studies in patients with RMDs who were only taking conventional DMARDs and/or prednisone < 20 mg daily at the time they received the yellow fever vaccine observed no cases of infection (63,64). Similarly, in a retrospective cohort study of patients with juvenile idiopathic arthritis (JIA) taking methotrexate and vaccinated against measles, mumps, and rubella (MMR), none developed vaccine-associated disease (65). Some pediatric rheumatologists do recommend giving live attenuated virus vaccine boosters (66) to children receiving low-dose immunosuppression when the child is likely to be taking the medication long term and when the risk of flare when not receiving immunosuppression is high, especially in areas with low community vaccination rates and/or during outbreaks (67). The AAP Red Book (15) and the Infectious Diseases Society of America (68) define low-level immunosuppression as methotrexate ≤ 0.4 mg/kg/week, azathioprine ≤ 3 mg/kg/day, prednisone < 20 mg/day (or < 2 mg/kg/day for patients weighing < 10 kg), or alternate-day glucocorticoid therapy (68).

Biologic DMARDs. In a large RCT of RMD patients taking TNFi who were given the live attenuated VZV vaccine, there were no confirmed cases of varicella infection in either the vaccine or placebo group during 1 year of follow-up (69). Similarly, in an observational study of patients with Kawasaki disease who received vaccines against rotavirus and/or MMR plus varicella within 90 days prior to a single dose of infliximab, none experienced any serious infections (70). Finally, in a study of RA patients given a yellow fever booster 1 month after their last dose of infliximab, none developed symptoms of yellow fever (71).

In contrast, in a very small retrospective study based on an email survey to pediatric and adult rheumatologists and immunologists that reported on 17 children with autoinflammatory disorders or systemic JIA taking interleukin-1 or interleukin-6 receptor inhibitors and who were given a variety of live attenuated vaccinations, 3 of 17 patients developed vaccine-associated infection, and 7 of 17 patients experienced disease flares (72).

JAK inhibitors. Cutaneous vaccine-strain varicella infection developed in 1 of 55 RA patients given a single dose of the live attenuated VZV vaccine 2–3 weeks prior to tofacitinib initiation in the context of an RCT. Later testing demonstrated that the study participant lacked prevaccination immunity to VZV (73). Complete lack of immunity to varicella is rare in adults in the US, where the prevalence of varicella seropositivity is 98% in adults (74).

Intravenous immunoglobulin (IVIG). Antiviral antibodies contained in IVIG can interfere with replication of live attenuated vaccines and reduce their efficacy (75). The CDC recommends a delay of 8–11 months (depending on IVIG dose) between receipt of high-dose IVIG and live attenuated virus vaccination (76). However, there will be situations, such as during a measles outbreak,

Table 5. Immunosuppressive medication management at the time of live attenuated virus vaccine administration*

	Hold before live attenuated virus vaccine administration	Hold after live attenuated virus vaccine administration
Glucocorticoids†	4 weeks	4 weeks
Methotrexate, azathioprine‡	4 weeks	4 weeks
Leflunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide	4 weeks	4 weeks
JAK inhibitors	1 week	4 weeks
TNF, IL-17, IL-12/23, IL-23, BAFF/BLYS inhibitors	1 dosing interval§	4 weeks
IL-6 pathway inhibitors	1 dosing interval¶	4 weeks
IL-1 inhibitors		
Anakinra	1 dosing interval¶	4 weeks
Rilonacept	1 dosing interval¶	4 weeks
Canakinumab	1 dosing interval¶	4 weeks
Abatacept	1 dosing interval§	4 weeks
Anifrolumab	1 dosing interval§	4 weeks
Cyclophosphamide, intravenous	1 dosing interval§	4 weeks
Rituximab	6 months	4 weeks
IVIg#		
300–400 mg/kg	8 months	4 weeks
1 gm/kg	10 months	4 weeks
2 gm/kg	11 months	4 weeks

* TNF = tumor necrosis factor; IL = interleukin; BLYS = B lymphocyte stimulator; IVIG = intravenous immunoglobulin.

† For patients taking the equivalent of prednisone <20 mg/day or <2 mg/kg/day for patients weighing <10 kg or alternate-day glucocorticoid therapy (i.e., “low-level immunosuppression” [15,68]), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency when the patient is not taking glucocorticoids is high.

‡ For patients taking methotrexate ≤0.4 mg/kg/week or azathioprine ≤3 mg/kg/day (“low-level immunosuppression” [15,68]), hold times can be shortened if vaccination is critical and the risk of a disease flare when the patient is not taking immunosuppression is high.

§ For medications with >1 dosing interval approved by the Food and Drug Administration, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks, although it can be dosed every 1 or every 2 weeks).

¶ In children with autoimmune disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic disease-modifying antirheumatic drugs are held is very high, shorter hold times can be considered if live attenuated vaccination is critical.

The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.

when earlier vaccination is preferred over delay because some immunity will be preferred over none in that setting.

Specific recommendations for holding medications if live attenuated vaccines are given. Although the evidence around the safety of conventional DMARDs and TNFi at the time of live attenuated virus vaccination is reassuring, the total number of RMD patients who have been studied is small, and the Voting Panel conditionally recommended against administering live attenuated virus vaccines to patients receiving

those agents as well as other forms of immunosuppression. For patients who do need to receive live attenuated vaccines, specific recommendations for holding immunosuppressive medications around the time of vaccination can be found in Table 5.

For slow-acting conventional DMARDs, a prevaccination hold time of 4 weeks was chosen to reflect their prolonged duration of action. However, direct evidence for the optimal hold time is lacking. For most biologic DMARDs, a hold time of 1 dosing interval before live attenuated vaccine administration is recommended.

The number of RMD patients who are taking immunosuppressive medications at the time that they need live attenuated virus vaccines is small. However, very young children, especially those with autoinflammatory disorders, may require biologic DMARDs before their primary vaccination series is complete. In these children, the risk associated with a disease flare may be considerably higher than the risk associated with the vaccine preventable illness (72). Children with autoinflammatory disorders also often require lifelong anticytokine therapy, and there may never be an opportunity to catch up on missed vaccinations later. For these children, shorter medication hold times can be considered if live attenuated virus vaccination is critical and cannot be delayed. Shared decision-making with the child's parents/guardians is important in this setting, and they should be alerted to the signs and symptoms of attenuated vaccine-associated infection.

The recommendation to hold immunosuppressive medications for 4 weeks after live attenuated vaccination is conservative. Typically, the duration of viremia (live virus circulating in the blood) after live attenuated vaccination is 2 weeks, although it can be longer in some patients (77). Viremia is more prolonged after primary vaccination than after booster vaccinations (77). Medication hold times after vaccination can be shortened if vaccination is critical and the risk of a disease flare when the patient is not receiving immunosuppression is high.

Close contacts of immunosuppressed patients should receive all age-appropriate vaccination (with the exception of smallpox) to avoid the vaccine-preventable diseases, as recommended by the ACIP (78). The ACIP also notes that no specific precautions are needed except if a household contact develops a rash after varicella vaccination, in which case direct contact should be avoided until the rash resolves (78). They also reinforce the recommendation to household members to wash their hands after diaper changing when an infant has received a rotavirus vaccine (78).

When to administer rotavirus vaccine to infants with second- and/or third-trimester antenatal exposure to biologic DMARDs in utero (Table 6).

For neonates/infants with second- and/or third-trimester antenatal exposure to TNFi, giving live attenuated rotavirus vaccine within the first 6 months of life is conditionally recommended.

For neonates/infants with second- and/or third-trimester antenatal exposure to rituximab, *delaying* live attenuated rotavirus vaccine until >6 months of age is conditionally recommended.

Vaccination against rotavirus typically occurs at 2 and 4 months, or at 2, 4, and 6 months. Rotavirus is rare in the US because of widespread immunization, and for this reason, the AAP recommends delaying rotavirus vaccination for 12 months after any in utero exposure to biologic DMARDs (except for certolizumab, which does not cross the placenta) (15). Three observational studies encompassing 58 children exposed to biologic DMARDs (most taking TNFi) who received live rotavirus vaccines reported no clear adverse events (79–81). Only minimal amounts of infliximab have been detected in the breast milk of treated patients (82).

The literature review identified no data on the effect of in utero rituximab exposure on later vaccine responses. Rituximab is a chimeric IgG1 molecule that can cross the placenta, and it has been associated with low or absent B lymphocyte levels in newborns who were exposed during the second or third (but not the first) trimester (83). Most reports demonstrate B cell recovery in these infants within 6 months after birth (83). Extrapolating from vaccine responses in adults treated with rituximab (48–50), infants exposed to rituximab are unlikely to respond to vaccination until 6 months postexposure. Although delayed rotavirus vaccine administration has been associated with an increased risk of intussusception, this complication remains quite rare (84).

After giving birth, most RMD patients turn to their general pediatrician rather than to their adult rheumatology provider for infant vaccination recommendations, and pediatricians may not be aware of the impact of in utero medication exposure on vaccine safety and immunogenicity. Therefore, recommendations regarding infant rotavirus vaccination after in utero exposure to either TNFi or rituximab should be discussed with the pregnant RMD patient prior to delivery. Specifically, the pregnant patient should be educated as to the fact that medications that cross the placenta may affect vaccination schedules for their infants. A copy of the current vaccine guideline summary (<https://www.rheumatology.org/Portals/0/Files/Vaccinations-Guidance-Summary.pdf>) may serve as a useful resource for the pregnant RMD patient to share with their pediatrician in advance of delivery.

Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*

Antenatal drug exposure in second or third trimester	Within the first 6 months of life	After 6 months of life
TNFi	Give rotavirus vaccine	–
Rituximab	Do not give rotavirus vaccine	Give rotavirus vaccine

□ = Conditional recommendation.

* TNFi = tumor necrosis factor inhibitor.

Whether to give multiple vaccinations to patients with RMD on the same day.

For patients with RMD, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended.

Administering >1 vaccination on a single day is a routine practice in both pediatric and adult medicine that is supported by the CDC in order to avoid a missed vaccination opportunity (85). Patient representatives on the Voting Panel felt that shared decision-making was important in this instance due to their concerns about the potential for reactogenicity or disease flare.

A summary of the guideline recommendations, associated PICO questions, and level of evidence can be found in Table 7.

DISCUSSION

This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD spectrum. An underlying principle in this guideline is that patients should be vaccinated, and that missed vaccination opportunities should be avoided or minimized. This is particularly true regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the recommendations are conditional and apply across diseases, vaccines, medications, and age groups. Because of the low quality of the evidence, shared decision-making between clinicians and patients/parents/guardians is particularly important for the vaccination strategies presented here. These recommendations do not supersede clinical judgement.

Most recommendations in this guideline are aimed at maximizing vaccine immunogenicity because the literature revealed few vaccine safety signals, at least regarding non-live vaccinations. Many vaccines are required for school entry to protect not only the health of the individual but also that of the broader community. Public health requirements may supersede some recommendations made here. Insurance barriers could inhibit implementation of these recommendations, such as to administer high dose or adjuvanted influenza vaccine or recombinant VZV to RMD patients <65 years of age taking immunosuppressive medications. In such instances, this guideline could be used as a resource to aid in prior authorization.

Not included in this guideline are recommendations for COVID-19 vaccination in patients with RMD. Readers can refer to the CDC for the most up-to-date recommendations for COVID-19 vaccination, including for patients taking immunosuppressive

Table 7. Summary of recommendations*

Recommendations	Level of evidence†	PICO	Evidence table page numbers
Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression			
Influenza vaccination			
For patients with RMD age ≥65 years and patients with RMD age >18 and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination.	PICO 9. Very low (indirect evidence only)‡	PICO 9. In patients with RMD age ≥65 years, is high-dose influenza vaccine more effective than seasonal regular-dose influenza vaccine?	728
	PICO 10. Very low (indirect evidence only)‡	PICO 10. In patients with RMD age ≥65 years, is adjuvanted influenza vaccine more effective than seasonal regular-dose influenza vaccine?	728
	PICO 11. Moderate	PICO 11. In patients with RMD <65 years of age, is high-dose vaccine more effective than seasonal regular-dose influenza vaccine?	728–737
	PICO 12. Very low (indirect evidence only)‡	PICO 12. In patients with RMD <65 years of age, is adjuvanted influenza vaccine more effective than seasonal regular-dose influenza vaccine?	737
Pneumococcal vaccination			
For patients with RMD age <65 years who are taking immunosuppressive medication, pneumococcal vaccination is strongly recommended.	PICO 20. Low	PICO 20. Should patients with RMD receive vaccination against pneumococcus at age <65 years?	933–952
Recombinant VZV vaccination			
For patients with RMD age >18 years who are taking immunosuppressive medication, administering the recombinant VZV vaccine is strongly recommended.	PICO 21. Very low (indirect evidence only)‡	PICO 21. Should patients with RMD receive VZV vaccination at age <50 years?	952
HPV vaccination			
For patients with RMD age >26 and <45 years who are taking immunosuppressive medication and are not previously vaccinated, vaccination against HPV is conditionally recommended.	PICO 19. Very low	PICO 19. Should patients with RMD be vaccinated against HPV at age >26 years?	931–933
Whether to hold immunosuppressive medication at the time of non-live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare			
For patients with RMD, <i>holding</i> methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows.	PICO 3. Very low for most comparisons, moderate for a few	PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]?	7–550
	PICO 15. TNFi: low; tocilizumab: very low; secukinumab: very low; tofacitinib: moderate; glucocorticoids: very low; abatacept: very low	PICO 15. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking drug Y as compared to those not taking drug Y at the time of vaccination?	754–898
	PICO 16. MTX: moderate; tofacitinib: low; other medications: indirect evidence only	PICO 16. Should patients with RMD taking drug Y hold their drug Y for a period of time prior to or after receiving (not live attenuated) vaccines?	898–927

(Continued)

Table 7. (Cont'd)

Recommendations	Level of evidence†	PICO	Evidence table page numbers
For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended.	PICO 3. Very low for most comparisons, moderate for a few	PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]?	7–550
	PICO 15. TNFi: low; tocilizumab: very low; secukinumab: very low; tofacitinib: moderate; glucocorticoids: very low; abatacept: very low	PICO 15. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking drug Y as compared to those not taking drug Y at the time of vaccination?	754–898
	PICO 16. MTX: moderate; tofacitinib: low; other medications: indirect evidence only	PICO 16. Should patients with RMD taking drug Y hold their drug Y for a period of time prior to or after receiving (not live attenuated) vaccines?	898–927
For patients with RMD, continuing immunosuppressive medications around the time of other (non-influenza) non-live attenuated vaccinations is conditionally recommended.	PICO 3. Very low for most comparisons, moderate for a few	PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]?	7–550
	PICO 16. MTX: moderate; tofacitinib: low; other medications: indirect evidence only	PICO 16. Should patients with RMD taking drug Y hold their drug Y for a period of time prior to or after receiving (not live attenuated) vaccines?	898–927
Timing vaccinations in patients receiving rituximab to maximize vaccine efficacy			
For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due.	PICO 17. Low	PICO 17. Should patients with RMD who are taking rituximab time non-live attenuated vaccine administration relative to the next dose of medication?	927–930
For patients with RMD receiving rituximab, <i>deferring</i> non-live attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and <i>delaying</i> rituximab for 2 weeks after vaccination, is conditionally recommended.			
Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity			
For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non-live attenuated vaccinations is strongly recommended.	PICO 4. Low for pneumococcal vaccines, very low for other vaccines	PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high-dose steroids as compared to those taking lower doses of steroids or those not taking steroids?	551–579
	PICO 14. Very low	PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high-dose steroids as compared to those taking lower doses of steroids or those not taking steroids?	739–754
For patients with RMD who are taking the equivalent of prednisone >10 mg daily but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended.	PICO 4. Low for pneumococcal vaccines, very low for other vaccines	PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high-dose steroids as compared to those taking lower doses of steroids or those not taking steroids?	551–579

(Continued)

Table 7. (Cont'd)

Recommendations	Level of evidence†	PICO	Evidence table page numbers
	PICO 14. Very low	PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high-dose steroids as compared to those taking lower doses of steroids or those not taking steroids?	739–754
For patients with RMD taking the equivalent of prednisone ≥ 20 mg daily, administering influenza vaccination is conditionally recommended.	PICO 14. Very low	PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high-dose steroids as compared to those taking lower doses of steroids or those not taking steroids?	739–754
For patients with RMD who are taking the equivalent of prednisone ≥ 20 mg daily, <i>deferring</i> non-live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone < 20 mg daily is conditionally recommended.	PICO 4. Low for pneumococcal vaccines, very low for other vaccines	PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high-dose steroids as compared to those taking lower doses of steroids or those not taking steroids?	551–579
Whether to defer vaccination in patients with high disease activity to maximize vaccine immunogenicity and/or avoid worsening disease activity			
For patients with RMD, giving non-live attenuated vaccinations is conditionally recommended regardless of patients' disease activity.	PICO 13. Very low	PICO 13. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients who have moderate to severely active underlying disease as compared to those in low disease activity or remission?	737–739
	PICO 18. Very low	PICO 18. Should moderately to severely ill patients with RMD with disease X defer vaccination (not live attenuated) until the disease is better controlled?	930–931
Managing immunosuppressive therapy at the time of live attenuated vaccination to avoid vaccine-associated illness			
For patients with RMD who are taking immunosuppressive medication, <i>deferring</i> live attenuated vaccines is conditionally recommended.	PICO 23. Very low	PICO 23. Should patients with RMD taking drug Y receive live attenuated vaccines?	952–960
For patients with RMD, <i>holding</i> immunosuppressive medication for an appropriate period before and 4 weeks after live attenuated virus vaccination is conditionally recommended.	PICO 24. Very low	PICO 24. Should patients with RMD taking drug Y hold the drug for a period of time prior to or after receiving live attenuated vaccines?	960–964
When to administer rotavirus vaccine to infants with second- and/or third-trimester antenatal exposure to biologic DMARDs in utero			
For neonates/infants with second- and/or third-trimester antenatal exposure to TNFi, giving live attenuated rotavirus vaccine within the first 6 months of life is conditionally recommended.	PICO 25. Very low	PICO 25. Should neonates/infants with second- and third- trimester antenatal exposure to TNFi or rituximab receive live attenuated rotavirus vaccine in their first 6 months of life?	964–966
For neonates/infants with second- and/or third-trimester antenatal exposure to rituximab, <i>delaying</i> live attenuated rotavirus vaccine until > 6 months of age is conditionally recommended.	PICO 25. Very low	PICO 25. Should neonates/infants with second- and third- trimester antenatal exposure to TNFi or rituximab receive live attenuated rotavirus vaccine in their first 6 months of life?	964–966
Whether to give multiple vaccinations to patients with RMD on the same day			

(Continued)

Table 7. (Cont'd)

Recommendations	Level of evidence [†]	PICO	Evidence table page numbers
For patients with RMD, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended.	PICO 22. Very low (indirect evidence only) [‡]	PICO 22. Should patients with RMD receive standardized regimens of vaccine combinations?	952

■ = Strong recommendation.

□ = Conditional recommendation.

* PICO = population, intervention, comparator, outcomes; RMD = rheumatic and musculoskeletal disease; VZV = varicella-zoster virus; HPV = human papillomavirus; MTX = methotrexate; TNFi = tumor necrosis factor inhibitors; DMARDs = disease-modifying antirheumatic drugs.

[†] The terms 'moderate', 'low', and 'very low' are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) definitions for quality of evidence. Moderate quality means that "further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate." Low quality means that "further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate." Very low quality means that "we are very uncertain about the estimate." In the systematic review for this guideline, a judgment of moderate quality required at least some evidence from randomized controlled trials, and a judgment of low quality required at least some evidence from well-designed observational studies with appropriate comparator groups.

[‡] Indirect evidence indicates that there is evidence from other populations with RMD or other health conditions, or evidence that does not fully address the comparison specified in a PICO question.

medication (9). Recommendations about holding immunosuppressive medications at the time of non-live attenuated virus vaccination in this guideline (Table 3) differ from those recommended around the time of COVID-19 vaccination in the ACR COVID-19 vaccine guidance (8). This is because prior to the introduction of COVID-19 vaccines in late 2020, there was little population-level immunity to the SARS-CoV-2 virus, and maximizing vaccine efficacy was a public health imperative. In contrast, when considering routine vaccinations, the desire to avoid an RMD flare weighs more heavily in the balance. Therefore, there are very few instances where this guideline recommends holding medication at the time of non-live attenuated virus vaccination. Studies that demonstrate diminished vaccine responses in RMD patients receiving immunosuppression (other than rituximab) generally demonstrate diminished, but not completely abrogated, responses.

Finally, the literature review demonstrated that much more evidence is needed to guide practice in this area. Knowledge gaps where further research is needed are as follows: 1) standardization of trial design and outcome measures to test the efficacy and durability of response to all vaccines across all age groups; 2) safety of primary and booster live attenuated virus vaccination in children taking methotrexate and/or biologic DMARDs; 3) assessment of the immunogenicity, reactogenicity, and disease flares following standard-dose, high-dose, and adjuvanted influenza vaccination, recombinant VZV vaccination, and primary and booster COVID-19 vaccination in RMD patients taking immunosuppressive medication; and 4) RCTs to test the safety and efficacy of holding DMARDs around the time of vaccination.

ACKNOWLEDGMENTS

We thank the patients who (along with authors Ida Hakkarinen and Grayson Schultz) participated in the Patient Panel meeting: Jacob

Anderson, Rachelle Crow-Hercher, Kathy Full, Sandra Nye, Mary Turner, Shilpa Venkatachalam, and Bene Williams. We thank the ACR staff, including Regina Parker, for assistance in coordinating the administrative aspects of the project, Cindy Force, for assistance with manuscript preparation, and Amy Turner, for overall supervision of the project. We thank Janet Waters for her assistance in developing the literature search strategy, as well as performing the initial literature search and update searches. We thank Susan Goodman, MD, for her help shepherding the project.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Bass had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Bass, Chakravarty, Akl, Bingham, Calabrese, Cappelli, Imundo, Winthrop, Baden, Curtis, Smith, Fontanarosa, Lakin, Sadun, Tam, Turner, Reston.

Acquisition of data. Chakravarty, Calabrese, Imundo, Baden, Bridges, Schultz, Calabrese, Cunha, Fontanarosa, Gillispie-Taylor, Gkrouzman, Iyer, Lakin, Legge, Lo, Lockwood, Sadun, Singh, Sullivan, Tam, Turgunbaev, Reston.

Analysis and interpretation of data. Bass, Chakravarty, Akl, Bingham, Calabrese, Cappelli, Johnson, Winthrop, Arasarathnam, Baden, Berard, Bridges, Cheah, Curtis, Ferguson, Hakkarinen, Onel, Schultz, Sivaraman, Smith, Sparks, Vogel, Williams, Calabrese, Fontanarosa, Gillispie-Taylor, Gkrouzman, Legge, Lockwood, Singh, Sullivan, Tam, Turgunbaev, Reston.

REFERENCES

1. American College of Rheumatology. Rheumatic diseases in America: the problem, the impact, and the answers. 2012. URL: https://www.bu.edu/enact/files/2012/10/ACR_Whitepaper_SinglePg.pdf.
2. Van der Heijde D, Daikh DI, Betteridge N, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers, and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). *Arthritis Rheumatol* 2018;70:826–31.

3. Freedman MS, Bernstein H, Ault KA, et al. Recommended adult immunization schedule, United States, 2021. *Ann Intern Med* 2021; 174:374–84.
4. Wodi A, Ault KA, Hunter P, et al. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger –United States, 2021. URL: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7006a1.htm#contri bAff>.
5. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. *Hum Vaccin Immunother* 2016; 12:2391–402.
6. Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) clinical research studies. URL: <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/studies.html>.
7. Centers for Disease Control and Prevention. Vaccine Administration. 2022. URL: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html>.
8. American College of Rheumatology. COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases. 2022. URL: <https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf>.
9. Centers for Disease Control and Prevention. COVID-19 vaccines for people who are moderately or severely immunocompromised. URL: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>.
10. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommendations. URL: <https://www.cdc.gov/vaccines/acip/recommendations.html>.
11. American Academy of Pediatrics. 2021. Immunizations. URL: <https://www.aap.org/en/patient-care/immunizations/>.
12. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. *J Clin Epidemiol* 2013;66:726–35.
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
14. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010;182:E839–42.
15. Kimberlin DW, Barnett ED, Lynfield R, et al. Red Book: 2021–2024 report of the Committee on Infectious Diseases. 32nd ed. Itasca (IL): American Academy of Pediatrics; 2021.
16. Stapleton JT, Wagner N, Tuetken R, et al. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: results of the DMID 10–0076 randomized clinical trial. *Vaccine* 2020;38:3934–41.
17. Colmegna I, Useche ML, Rodriguez K, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. *Lancet Rheumatol* 2020;2:e14–23.
18. Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. *Hum Vaccin Immunother* 2018;14:550–64.
19. Heusele M, Clerson P, Guery B, et al. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. *Clin Rheumatol* 2014;33:799–805.
20. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. *Open Forum Infect Dis* 2014;1:ofu024.
21. Centers for Disease Control and Prevention. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. URL: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w.
22. Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. 2022. URL: <https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>.
23. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. *Arthritis Rheumatol* 2016;68:2328–37.
24. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. *Clin Infect Dis* 2020;70:181–90.
25. Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. *JAMA* 2019;322:123–33.
26. Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. *Lancet Infect Dis* 2019;19:988–1000.
27. Stadtmauer EA, Sullivan KM, El Idrissi M, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. *Hum Vaccin Immunother* 2021;17:4144–54.
28. Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. *Rheumatology (Oxford)* 2021;60:5149–57.
29. Feldman CH, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. *Lupus* 2017;26:682–9.
30. Garland SM, Brotherton JM, Moscicki AB, et al. HPV vaccination of immunocompromised hosts. *Papillomavirus Res* 2017;4:35–8.
31. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. *Ann Rheum Dis* 2015; 74:1360–7.
32. Kim SC, Schneeweiss S, Liu J, et al. Biologic disease-modifying anti-rheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: a cohort study. *Arthritis Rheumatol* 2016;68:2106–13.
33. Wadstrom H, Frisell T, Sparen P, et al. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. *Ann Rheum Dis* 2016; 75:1272–8.
34. Dhar JP, Essenmacher L, Dhar R, et al. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. *Vaccine* 2017;35:2642–6.
35. Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. *Ann Rheum Dis* 2013;72: 659–64.
36. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease: a prospectively controlled vaccination study. *Rheumatology (Oxford)* 2012;51:695–700.
37. Ribeiro AC, Guedes LK, Moraes JC, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. *Ann Rheum Dis* 2011;70:2144–7.
38. Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis* 2017;76: 1559–65.

39. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis* 2018;77:898–904.
40. Araujo CS, Medeiros-Ribeiro AC, Saad CG, et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. *Ann Rheum Dis* 2022;81:889–97.
41. Arumahandi de Silva AN, Frommert LM, Albach FN, et al. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. *Ann Rheum Dis* 2022;81:881–8.
42. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. *J Rheumatol* 2007;34:272–9.
43. Kivitz AJ, Schechtman J, Texter M, et al. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. *J Rheumatol* 2014;41:648–57.
44. Alten R, Bingham CO III, Cohen SB, et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. *BMC Musculoskelet Disord* 2016;17:231.
45. Richi P, Martin MD, de Ory F, et al. Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. *RMD Open* 2019;5:e001018.
46. Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. *Mod Rheumatol* 2012;22:871–6.
47. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. *Ann Rheum Dis* 2016;75:687–95.
48. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. *Vaccine* 2011;29:1643–8.
49. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. *Arthritis Rheum* 2011;63:1486–96.
50. Westra J, van Assen S, Wilting KR, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. *Clin Exp Immunol* 2014;178:40–7.
51. Bingham CO III, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum* 2010;62:64–74.
52. Nived P, Jonsson G, Settergren B, et al. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. *Arthritis Res Ther* 2020;22:36.
53. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. *J Rheumatol* 2002;29:2555–7.
54. Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. *Arthritis Rheum* 2011;63:2396–406.
55. Ristow SC, Douglas RG Jr, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. *Ann Intern Med* 1978;88:786–9.
56. Borba EF, Saad CG, Pasoto SG, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? *Rheumatology (Oxford)* 2012;51:1061–9.
57. Campos LM, Silva CA, Aikawa NE, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza A vaccine in patients with juvenile systemic lupus erythematosus. *Arthritis Care Res (Hoboken)* 2013;65:1121–7.
58. Guissa VR, Pereira RM, Sallum AM, et al. Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. *Clin Exp Rheumatol* 2012;30:583–8.
59. Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study. *Vaccine* 2017;35:4877–85.
60. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. *J Rheumatol* 2007;34:952–7.
61. Winthrop KL, Bingham CO III, Komocsar WJ, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. *Arthritis Res Ther* 2019;21:102.
62. Launay O, Paul S, Servettaz A, et al. Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine. *Vaccine* 2013;31:3492–501.
63. Valim V, Machado K, Miyamoto ST, et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective non-interventional study. *Front Immunol* 2020;11:1382.
64. Wieten RW, Jonker EF, Pieren DK, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication. *Vaccine* 2016;34:1247–51.
65. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. *Ann Rheum Dis* 2007;66:1384–7.
66. Uziel Y, Moshe V, Onozo B, et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. *Vaccine* 2020;38:2198–201.
67. Quinn SC, Jamison AM, Freimuth VS. Measles outbreaks and public attitudes towards vaccine exemptions: some cautions and strategies for addressing vaccine hesitancy. *Hum Vaccin Immunother* 2020;16:1050–4.
68. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014;58:e44–100.
69. Curtis JR, Cofield SS, Bridges SL Jr, et al. The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: a randomized controlled trial. *Ann Intern Med* 2021;174:1510–8.
70. Lee AM, Burns JC, Tremoulet AH. Safety of infliximab following live virus vaccination in Kawasaki disease patients. *Pediatr Infect Dis J* 2017;36:435–7.
71. Scheinberg M, Guedes-Barbosa LS, Manguera C, et al. Yellow fever revaccination during infliximab therapy. *Arthritis Care Res (Hoboken)* 2010;62:896–8.
72. Jeyaratnam J, Ter Haar NM, Lachmann HJ, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. *Pediatr Rheumatol Online J* 2018;16:19.
73. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. *Arthritis Rheumatol* 2017;69:1969–77.

74. Reynolds MA, Kruszon-Moran D, Jumaan A, et al. Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999–2004. *Public Health Rep* 2010;125:860–9.
75. Morikawa Y, Sakakibara H, Kimiya T, et al. Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease. *Vaccine* 2021;39:5680–7.
76. Centers for Disease Control and Prevention. Appendix A: schedules and recommendations. URL: <https://www.cdc.gov/vaccines/pubs/pinkbook/appendix/appdx-a.html>.
77. Papp KA, Haraoui B, Kumar D, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. *J Cutan Med Surg* 2019;23:50–74.
78. Centers for Disease Control and Prevention. Altered immunocompetence. URL: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>.
79. Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. *Clin Gastroenterol Hepatol* 2018;16:99–105.
80. Chiarella-Redfern H, Lee S, Jubran B, et al. Suboptimal vaccination administration in mothers with inflammatory bowel disease and their biologic-exposed infants. *Inflamm Bowel Dis* 2022;28:79–86.
81. Lee KE, Jung SA, Park SH, et al. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. *Intest Res* 2019;17:237–43.
82. Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. *J Crohns Colitis* 2011;5:555–8.
83. Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. *Expert Rev Vaccines* 2016;15:239–56.
84. Koch J, Harder T, von Kries R, et al. Risk of intussusception after rotavirus vaccination. *Dtsch Arztebl Int* 2017;114:255–62.
85. Centers for Disease Control and Prevention. Timing and spacing of immunobiologics. URL: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#:~:text=Two%20or%20more%20injectable%20or,the%20potential%20risk%20for%20interference.>